Hyperbilirubinemia is reported to have occurred in a newborn if the drug is given excessively from the recommended dose.
Cyanosis, peripheral vascular collapse, hot flushes, sweating, chest pain, hyperhidrosis, shock, hypersensitivity reactions, including anaphylactic reactions and deaths reported by intravenous administration. Giving intravenously should be avoided.
Local irritations such as pain, swelling and tenderness may occur to the recent injection site.
Parenteral administration of newborns / neonates may cause hemolytic anemia and hemoglobinuria.